SCHEMBL2789480

SCHEMBL2789480

Fc1c(F)c(F)c(-c2n[nH]c(-c3ccccn3)n2)c(F)c1F

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.71
RAB9A P51151 4/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
L3MBTL1 Q9Y468 2/20 0.71
TDP1 Q9NUW8 2/20 0.71
PKM P14618 2/20 0.71
ALPL P05186 1/20 0.71
ALOX15 P16050 1/20 0.71
HSD17B10 Q99714 1/20 0.71
KDM4E B2RXH2 3/20 0.61
NOTUM Q6P988 1/20 0.55
F2 P00734 2/20 0.48
F12 P00748 2/20 0.48
PLAU P00749 1/20 0.48
BTK Q06187 1/20 0.45
CBFB Q13951 3/20 0.43
METAP1 P53582 5/20 0.41
METAP2 P50579 4/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31565158 1.00 NPC1 (0.71) NPC1RAB9ASMN1; SMN2L3MBTL1TDP1
SCHEMBL31565167 1.00 NPC1 (0.71) NPC1RAB9ASMN1; SMN2L3MBTL1TDP1
SCHEMBL2788521 0.86 NPC1 (0.69) NPC1RAB9ASMN1; SMN2L3MBTL1TDP1
SCHEMBL8311588 0.83 SMN1; SMN2 (1.00) NPC1RAB9ASMN1; SMN2L3MBTL1TDP1
SCHEMBL2791438 0.80 NPC1 (0.77) NPC1RAB9ASMN1; SMN2L3MBTL1TDP1
SCHEMBL2789192 0.79 NPC1 (0.70) NPC1RAB9ASMN1; SMN2L3MBTL1TDP1
SCHEMBL31565163 0.79 SMN1; SMN2 (0.81) NPC1RAB9ASMN1; SMN2L3MBTL1TDP1
SCHEMBL2251038 0.79 NPC1 (1.00) NPC1RAB9ASMN1; SMN2L3MBTL1TDP1
SCHEMBL31565162 0.79 SMN1; SMN2 (0.81) NPC1RAB9ASMN1; SMN2L3MBTL1TDP1
SCHEMBL31565161 0.76 SMN1; SMN2 (0.82) NPC1RAB9ASMN1; SMN2L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170911-B1 LIGHT EMITTING CU(I) COMPLEXES UDC IRELAND LTD (IE) 2018-11-28 EP disclosed
US-8440826-B2 Light emitting Cu (I) complexes BASF SE (DE) 2013-05-14 US disclosed
US-20100252820-A1 LIGHT EMITTING CU (I) COMPLEXES CIBA CORPORATION (US) 2010-10-07 US disclosed
EP-2170911-A2 LIGHT EMITTING CU(I) COMPLEXES BASF SE (DE) 2010-04-07 EP disclosed
WO-2009000673-A2 LIGHT EMITTING CU(I) COMPLEXES BASF SE (CH) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100252820-A1 LIGHT EMITTING CU (I) COMPLEXES CLTA, CLTB, CLTC NPC1 3588/4885RAB9A 2620/4885SMN1; SMN2 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.